ABIVAX：在反对乙肝斗争的新武器

hao2014

回复 StephenW 的帖子

这个当然是的

毫无疑问

难道是在钓鱼？？？

9病成医

StephenW 发表于 2015-6-25 20:59
回复 9病成医 的帖子

对不起，我不同意.

影响药品临床试验进度的因素很多，但关于人权方面的考虑占较大比重，古巴在这方面恰恰有优势。

StephenW

http://www.newindianexpress.com/ ... /article2946543.ece

BHUBANESWAR: Even as Hepatitis B virus (HBV) claims nearly one million deaths worldwide every year, a new drug holds immense promise for treatment and cure of the chronic infection.

With clinical trials in advanced stages across several countries in Asia, Asia Pacific region, Latin America, Europe and Australia, the novel therapeutic vaccine NasVac could be available for use in as early as 2018-19, hepatologist and secretary general of Association for the Study of Liver, Bangladesh Dr Mamun-Al-Mahtab said on Tuesday.

NasVac induces a much effective immune response to the virus in the body, leading to control of virus replication and ultimate elimination from the body. The therapeutic vaccine cannot be called a wonder drug but has shown to have a response rate of more than 50 per cent, Dr Mahtab said.

As of now, there is no cure for HBV and conventional treatment aims at suppressing the HBV proteins to slow down progression to complications like cirrhosis and liver cancer and improve long-term survival rates. However, the treatment has its side effects and even leads to drug resistance.

“NasVac opens a new avenue for HBV treatment. After successful trials, the drug is now set to be registered in Cuba and Latin American countries like Ecuador, Venezuela and Brazil this year. Europe is likely to register it by 2018 and hopefully by 2019, it would be open across the world,” the researcher and expert said.
http://www.newindianexpress.com/ ... /article2946543.ece

BHUBANESWAR：即使乙肝病毒（HBV）声称，在全球近百万人死亡，每年都有新的药物拥有巨大诺言为治疗慢性感染和治疗。

在高级阶段跨越几个亚洲国家，亚太地区，拉丁美洲，欧洲和澳大利亚的临床试验中，新型治疗性疫苗NasVac可以在可供使用早在2018-19，协会肝病和秘书长的研究肝，孟加拉国马蒙博士 - 铝 - Mahtab周二表示。

NasVac诱导对在体内的病毒更有效的免疫应答，导致控制病毒复制和最终从体内消除的。而治疗性疫苗不能被称为一个神奇的药物，但已经显示有超过50％的回应率，Mahtab博士说。

截至目前，没有治愈乙肝和常规治疗的目的是抑制乙肝病毒蛋白的进展减慢像肝硬化和肝癌的并发症和提高长期生存率。然而，在治疗有其副作用，甚至导致耐药性。

“NasVac打开用于乙肝治疗的新途径。经过试验取得成功，该药物现在被设置为在古巴和拉丁美洲国家厄瓜多尔一样，委内瑞拉和巴西今年登记。欧洲很可能将其注册到2018年，希望到2019年，这将是在世界各地开“的研究人员和专家说。

StephenW

孟加拉国Dr Mamum - AL - Mahtab过去进行ABX203并且REP9AC的临床试验。

ztwuhao

未来的新药就是乙肝人的希望，只要活着就有希望，等待！

StephenW

Cuban Vaccine Against Chronic Hepatitis B in Evaluation         PDF         Imprimir         E-Mail

Havana, Aug 10 (Prensa Latina) The Cuban vaccine for the treatment of chronic hepatitis B, (HeberNasvac, created by scientists from the Center for Genetic Engineering and Biotechnology (CIGB, in Spanish), is under clinical evaluation in collaboration with the French company Abivax.
For several years, clinical trials to evaluate the safety and efficacy of this product are made, noted a source at the CIGB.

The clinical trial that Cuban scientists conducted in conjunction with Abivax ABX runs under the code 203, and it involves about 230 patients from eight Asian countries, with the participation of 50 clinical sites, explained Iris Lugo Carro, specialist of the Cuban institution.

So far, the study has been approved by regulatory authorities in Australia, New Zealand, Singapore, South Korea, Taiwan, Hong Kong, Philippines and Thailand.

The clinical protocol was designed by experts of the highest scientific standards employed by Abivax, in collaboration with Cuban scientists. The research runs successfully in this region of the world, the most affected by the virus.

The Chronic liver disease caused by hepatitis B virus (HBV) is a major cause of liver cirrhosis and other complications such as ascites, esophageal varices and splenomegaly, with high-cost of health.

Each year, nearly one million deaths are elacionan with HBV infection, according to figures from the World Health Organization (WHO).

A second clinical trial was carried out in Cuba with the participation of the Public Health Ministry, to optimize the treatment regimen and route for the administration of the product.

The Center for Genetic Engineering and Biotechnology expects that HeberNasvac will start to be used in Cuba in 2016, after obtaining the consent of the sanitary registration granted by the Center for State Control of Drugs, equipment and Medical Devices.

In Cuba, the workers related to this vaccine received the Annual Award of the Academy of Sciences on several occasions.

StephenW

古巴对疫苗治疗慢性乙型肝炎的评价

哈瓦那8月10日（新闻报拉丁）古巴疫苗治疗慢性乙型肝炎的治疗，（HeberNasvac，从中心的遗传工程和生物技术（CIGB，西班牙语）的科学家创建的，是根据临床评价的协作与法国公司Abivax。
几年来，临床试验，以评估该产品的安全性和有效性制成，注意到在CIGB的来源。

这古巴科学家结合Abivax ABX进行的临床试验中的代码203下运行，它涉及八个亚洲国家的约230例，有50个临床中心参与，解释虹膜卢戈卡罗，古巴机构的专家。

到目前为止，这项研究已通过监管部门批准在澳大利亚，新西兰，新加坡，韩国，台湾，香港，菲律宾和泰国。

临床协议是通过由Abivax与古巴科学家采用的协作，在最高的科学标准专家设计的。该研究在世界的这一地区成功运行，受影响最严重的病毒。

由乙型肝炎病毒（HBV）慢性肝病是肝硬化和其他并发症如腹水，食管静脉曲张和脾肿大，与健康的高成本的主要原因。

每一年，近百万人死于与elacionan HBV感染，据世界卫生组织的数据（WHO）。

第二个临床试验进行了与古巴公共卫生部的参与，以优化治疗方案和路线产品的管理。

该中心的遗传工程和生物技术预计HeberNasvac将开始被使用在古巴在2016年，获得授予的中心药品，设备和医疗器械的国家控制的卫生注册的同意后。

在古巴，与此相关的疫苗工人收到几次科学院的年度大奖。

jaylongli

意思说最早2018年 可上市？

StephenW

回复 jaylongli 的帖子

预计HeberNasvac将开始被使用在古巴在2016年

jaylongli

回复 StephenW 的帖子

这又是什么药？没听说过。
基因免疫治愈？